Business Summary: Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
Financial Summary: BRIEF: For the nine months ended 31 March 2026, Accuray Inc revenues decreased 9% to $301M. Net loss increased from $2.7M to $47.3M. Revenues reflect Product segment decrease of 21% to $131.9M, China segment decrease of 50% to $46.6M, Japan segment decrease of 14% to $32.9M. Higher net loss reflects Interest expense increase from $8.7M to $24.2M (expense), Income from equity method investment decrease of 66% to $1.3M (income).